Policy Makers

/ Policy Makers

Policymakers at the local, national, and regional levels are confronted with a number of critical issues concerning the regulatory recognition of DTx products and the legislative actions required to enable public payer coverage and patient access.

MavenDTx promotes industry core principles and best practises to ensure that patients and clinicians have access to dependable therapies that consistently show meaningful outcomes. DTx products can more easily reach high-risk, rural, and underserved communities that often lack access to healthcare services even in the best of times, thanks to the ease of product scalability and access provided by patient-owned devices.

DTx in the Covid-19 Era:

Digital therapeutic products provide solutions to healthcare leaders looking for new ways to address increasing mental health challenges caused or exacerbated by Covid-19, allow patients with chronic diseases to control their conditions outside of traditional office settings, and reduce unnecessary burdens placed on overburdened clinicians and healthcare organisations.

“In the context of the Covid-19 public health emergency, the use of digital health technologies, including software as a medical device or other digital therapeutics solutions, may improve mental health and well-being of patients with psychiatric conditions during periods of shelter-in-place, isolation, and quarantine,” according to the US Food and Drug Administration. Furthermore, the use of such technologies has the potential to facilitate “social distancing” by reducing patient contact with, and proximity to, health care providers, as well as ease the burden on hospitals, other health care facilities, and health care professionals who are experiencing increased demand as a result of the Covid-19 public health emergency”.